[go: up one dir, main page]

WO2001011361A3 - Kit and method to assess the malignancy of neoplasias - Google Patents

Kit and method to assess the malignancy of neoplasias Download PDF

Info

Publication number
WO2001011361A3
WO2001011361A3 PCT/EP2000/007557 EP0007557W WO0111361A3 WO 2001011361 A3 WO2001011361 A3 WO 2001011361A3 EP 0007557 W EP0007557 W EP 0007557W WO 0111361 A3 WO0111361 A3 WO 0111361A3
Authority
WO
WIPO (PCT)
Prior art keywords
marker
antibodies
hormone
kit
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/007557
Other languages
French (fr)
Other versions
WO2001011361A2 (en
Inventor
Juergen A Frerichs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MONOTEC GmbH
Original Assignee
MONOTEC GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MONOTEC GmbH filed Critical MONOTEC GmbH
Priority to EP00956391A priority Critical patent/EP1240520A2/en
Priority to JP2001515966A priority patent/JP2003506716A/en
Priority to AU68353/00A priority patent/AU6835300A/en
Publication of WO2001011361A2 publication Critical patent/WO2001011361A2/en
Publication of WO2001011361A3 publication Critical patent/WO2001011361A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a diagnostic kit and use thereof for the stratification of patients for a treatment of hormone-dependent benign and malignant neoplasias. The kit contains antibodies that are directed against to a proliferation marker, preferably the Ki-67 protein, MCM, PCNA, Cyclines, phosphorylated histones, etc., and in particular the Ki-67 protein, on the one hand, and antibodies that are directed against a second marker selected form the group of hormone receptors such as the estrogen receptor, apoptotic marker like caspase cleaved cytokeratine 18 as defined by the mAb CD30, and bcl-2; transforming cell markers or tumor cell markers, like Her-2/neu on the other hand. The marker indices (e.g. Ki-67 marker index and hormone receptor status) generated with the aid of the antibodies can be set related to each other and serve for an optimal determination of the form of treatment.
PCT/EP2000/007557 1999-08-04 2000-08-03 Kit and method to assess the malignancy of neoplasias Ceased WO2001011361A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00956391A EP1240520A2 (en) 1999-08-04 2000-08-03 Kit and method to assess the malignancy of neoplasias
JP2001515966A JP2003506716A (en) 1999-08-04 2000-08-03 Diagnostic kit and its use
AU68353/00A AU6835300A (en) 1999-08-04 2000-08-03 Diagnostic kit and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19936618.7 1999-08-04
DE1999136618 DE19936618A1 (en) 1999-08-04 1999-08-04 Diagnostic kit and its use

Publications (2)

Publication Number Publication Date
WO2001011361A2 WO2001011361A2 (en) 2001-02-15
WO2001011361A3 true WO2001011361A3 (en) 2001-11-15

Family

ID=7917102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007557 Ceased WO2001011361A2 (en) 1999-08-04 2000-08-03 Kit and method to assess the malignancy of neoplasias

Country Status (5)

Country Link
EP (1) EP1240520A2 (en)
JP (1) JP2003506716A (en)
AU (1) AU6835300A (en)
DE (1) DE19936618A1 (en)
WO (1) WO2001011361A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361460B2 (en) 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases
WO2005033333A2 (en) * 2003-10-07 2005-04-14 Dako Denmark A/S Methods and compositions for the diagnosis of cancer
CA2642051C (en) 2006-02-09 2017-01-24 University Of South Florida Detection of cancer by elevated levels of bcl-2
RU2711452C2 (en) * 2014-01-22 2020-01-17 Конинклейке Филипс Н.В. Improved stratification of patients to evaluate therapy suitability
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
JP6854246B2 (en) 2015-06-08 2021-04-07 アーケア ダイアグノスティクス リミテッド How to analyze urine sample
EP3761031A4 (en) 2018-02-28 2022-06-01 Nitto Boseki Co., Ltd. Method for isolating cell nuclei having enhanced antigenicity from immobilized cells or ffpe tissue section, and antigen activator and kit therefor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312752A (en) * 1989-07-31 1994-05-17 Trustees Of Boston University Specific antibodies against the DNA-binding domain of and immunoassays to determine the presence and functional status of estrogen receptor proteins
EP0806668A2 (en) * 1996-05-10 1997-11-12 Becton, Dickinson and Company Method and kit for determining malignant potential in tissue cells
WO1999004238A2 (en) * 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders
US6007996A (en) * 1995-12-12 1999-12-28 Applied Spectral Imaging Ltd. In situ method of analyzing cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744356A (en) * 1989-07-31 1998-04-28 Trustees Of Boston University Specific antibodies against an epitope existing within the A/B region of estrogen receptor proteins
WO1997016731A1 (en) * 1995-11-02 1997-05-09 Thomas Jefferson University Immunocytochemical staining of exfoliated cervical samples

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312752A (en) * 1989-07-31 1994-05-17 Trustees Of Boston University Specific antibodies against the DNA-binding domain of and immunoassays to determine the presence and functional status of estrogen receptor proteins
US6007996A (en) * 1995-12-12 1999-12-28 Applied Spectral Imaging Ltd. In situ method of analyzing cells
EP0806668A2 (en) * 1996-05-10 1997-11-12 Becton, Dickinson and Company Method and kit for determining malignant potential in tissue cells
WO1999004238A2 (en) * 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DELLAS ATHANASSIOS ET AL: "Investigation of the Bcl-2 and C-myc expression in relationship to the Ki-67 labelling index in cervical intraepithelial neoplasia.", INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, vol. 16, no. 3, 1997, pages 212 - 218, XP000980205, ISSN: 0277-1691 *
SACCANI JOTTI G ET AL: "PRELIMINARY STUDY ON ONCOGENE PRODUCT IMMUNOHISTOCHEMISTRY C-ERBB-2 C-MYC RAS P21 EGFR IN BREAST PATHOLOGY", INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol. 7, no. 1, 1992, pages 35 - 42, XP000980522, ISSN: 0393-6155 *
See also references of EP1240520A2 *

Also Published As

Publication number Publication date
JP2003506716A (en) 2003-02-18
DE19936618A1 (en) 2001-03-15
WO2001011361A2 (en) 2001-02-15
AU6835300A (en) 2001-03-05
EP1240520A2 (en) 2002-09-18

Similar Documents

Publication Publication Date Title
WO2001098357A3 (en) Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
WO2003048328A3 (en) Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
IL144559A0 (en) Antibodies for cancer therapy and diagnosis
WO2003055443A3 (en) Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
WO2002006317A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
IL156618A0 (en) Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
WO1998058052A3 (en) Disease associated protein kinases
EP0753072A1 (en) Biological markers of benign prostate hyperplasia
WO2001025791A3 (en) Prostate cancer marker proteins
ATE292468T1 (en) USE OF BIOGENIC ESTROGEN SULFAMATES FOR HORMONE SUBSTITUTION THERAPY
WO2001011361A3 (en) Kit and method to assess the malignancy of neoplasias
EP1433792A8 (en) Human receptor proteins, related reagents and methods
WO2005070456A8 (en) Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
PT939809E (en) TIE-2 RECEIVER LIGANDS (TIE LINK 3 AND TIE LINK 4) AND YOUR USES
WO2002058538A3 (en) Methods of imaging and targeting vasculature
WO2002057786A3 (en) Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
WO1999031128A3 (en) Human tumor necrosis factor-r2-like proteins
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
WO2004083241A3 (en) Btc-interacting proteins and use thereof
Davio et al. H1 and H2 histamine receptors in human mammary carcinomas
EP1512755A3 (en) Markers for prostate cancer
WO2000039154A8 (en) Peptides of the at1 receptor and their use for preeclampsia and malign hypertension
AU2185000A (en) Treatment of diseases involving cyst formation
WO2003058198A3 (en) Human breast cancer biomarkers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000956391

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10048910

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000956391

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 2000956391

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000956391

Country of ref document: EP